AGC Pharma Chemicals Europe DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News

AGC Pharma Chemicals to Attend the 54th Organic Process R&D Conf.

26 Sep 2025

// PRESS RELEASE

AGC Pharma Chemicals Launches €100M Plant In Spain

25 Sep 2025

// PRESS RELEASE

Power of Small Particles: Micronization in Small Molecule APIs

26 Jun 2025

// PRESS RELEASE

DATA COMPILATION
#PharmaFlow

Contact Supplier

Website

CPhI WW Frankfurt

Booth #6.0B44

Book a meeting

envelop Contact Supplier

DIGITAL CONTENT

3 Corporate Content #SupplierSpotlight, 1 Data Compilation #PharmaFlow, 22 News #PharmaBuzz

media
3 Corporate Content #SupplierSpotlight
1 Data Compilation #PharmaFlow
22 News #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

7 All APIs, 2 KDMF, 1 VMF, 6 Listed APIs

7 All APIs
2 KDMF
1 VMF
6 Listed APIs

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

INTERMEDIATES

1 All Intermediates

1 All Intermediates

KEY PRODUCTS

Dipyridamole, Gliquidone, Mexiletine, Pimobendan, Pirenzepine, Telmisartan

Dipyridamole
Gliquidone
Mexiletine
Pimobendan
Pirenzepine
Telmisartan

SERVICES

Analytical, API Manufacturing, API & Drug Product Development

pharmaServices
Analytical
- 1 Analytical Method Development
API Manufacturing
API & Drug Product Development
- 7 API Development

KEY SERVICES

CDMO for Small Molecules, CDMO for HPAPIs, API Scale-Up Capabilities, cGMP Micronization, GMP Manufacturing, API Scale-Up, cGMP Kilolab

CDMO for Small Molecules
CDMO for HPAPIs
API Scale-Up Capabilities
cGMP Micronization
GMP Manufacturing
API Scale-Up
cGMP Kilolab

Your reliable CDMO partner - agile, scalable, top-quality Small Molecule API & HPAPI solutions from concept to market

About

AGC Pharma Chemicals Europe is your essential CDMO partner for Small Molecule APIs/HPAPIs and Intermediates. We offer a complete range of services throughout the entire life cycle of API and HPAPI process development and manufacturing. We deliver comprehensive, agile, innovative solutions for your project, from clinical phase I to the commercial phase. Our commitment to the top pharma quality standards is reflected in all our processes. Guided by our vision: To be the first-choice CDMO and the most trusted partner, our mission:To improve people’s lives by delivering our best quality products and services.

CPhI WW FrankfurtCPhI WW Frankfurt

Industry Trade Show

Booth #6.0B44

28-30 October, 2025

Frankfurt
CPhI IndiaCPhI India

Industry Trade Show

Booth #RH.J01

25-27 November, 2025

India Expo Centre, Greater Noida
DCATDCAT

Industry Trade Show

Attending

23-26 March, 2026

New York, USA

CONTACT DETAILS

Click the arrow to open the dropdown

Country

Spain

Address

Camí de la Pomereda, 13 08380 Malgrat de Mar (Barcelona)

Telephone

apce.malsm.contact@agc.com

Website

https://www.agcpharmachemicals.com/

https://www.linkedin.com/company/agc-pharma-chemicals-europe-s-l-u/

YouTube

http://www.youtube.com/@AGCPharmaChemicals

Digital content

Explore the latest content creation from this company

CORPORATE CONTENT #SupplierSpotlight

Product List 2025

Open PDF

Upload

Corporate Video

GMP New Kilo Lab with HAPI Capability

DATA COMPILATION #PharmaFlow

CDMO Activity Tracker: Veranova, ChemExpress invest in ADC facilities; Cohance to set up oligonucleotide facility in India

The contract development and manufacturing organization (CDMO) sector has emerged as a key partner in new drug development. This was evident from the strategic investments, partnerships, and expansions witnessed in the third quarter (Q3) of 2025. Several CDMOs, such as Cohance Lifesciences, Fermion Oy, Axplora, AGC Pharma Chemicals invested in new projects. Others, including Veranova, Aenova, and Biosynth, expanded capacities, while Ofichem strengthened its footprint with the acquisition of Avivia BV. CDMOs like Fareva, Evonik, and Samsung Biologics forged strategic partnerships for growth. During Q3, the sector continued to adopt artificial intelligence (AI). This prompted the US Food and Drug Administration (FDA) to issue guidance that recognizes the increasing use of AI and data analytics in drug development. View CDMO Activity Tracker for Q3 2025 (Free Excel Available) Cohance, Veranova invest in bioconjugation suites in US; ChemExpress inks ADC deal Earlier this year, Indian drugmaker Suven Pharmaceuticals Limited merged with leading CDMO Cohance Lifesciences Limited. The merged entity — Cohance Lifesciences — has invested US$ 10 million in a current Good Manufacturing Practice (cGMP) bioconjugation suite at its subsidiary NJ Bio in Princeton, New Jersey. NJ Bio is executing a major program for an existing innovator client with multiple antibody-drug conjugate (ADC) candidates. Cohance also announced an INR 230 million (approximately US$ 2.58 million) investment in a cGMP oligonucleotide facility at its Hyderabad (India) site. Veranova’s Devens (Massachusetts) site successfully passed a routine FDA cGMP surveillance inspection with a “No Action Indicated” (NAI) classification. Earlier, the company had initiated a US$ 50 million investment to expand its ADC and bioconjugate capabilities at its Devens site. This includes a 9,000-square-foot facility expansion with a new process development lab, two additional cGMP suites, and state-of-the-art bioconjugation development and manufacturing capabilities. These initiatives strengthen the site’s highly potent API (HPAPI) and ADC development and manufacturing capabilities. Biosynth has expanded its Berlin facility with a new GMP bioconjugation suite. The expansion supports the company’s manufacturing capabilities in conjugate vaccines, conjugate drugs, activated polyethylene glycol (PEGs), and polymer-based drug delivery excipients. ChemExpress, Mabwell Bioscience, and Insilico Medicine have entered into a strategic partnership to jointly develop a large ADC compound library and advance next-generation ADC candidates. The collaboration combines Mabwell’s antibody and ADC technology, Insilico’s AI-powered drug design platform, and ChemExpress’s expertise in linker-payload chemistry. Together, they aim to build a complete, AI-driven ADC development model that accelerates discovery, optimization, and commercialization. This partnership is expected to enhance R&D efficiency and deliver safer, more effective cancer treatments. View CDMO Activity Tracker for Q3 2025 (Free Excel Available) Fermion, Axplora, Aenova increase API manufacturing capacities; ICE Pharma expands India facility Finnish CDMO Fermion Oy has launched a renovation project at its Hanko (Finland) production site to modernize its API manufacturing capabilities. This expansion is part of Fermion's broader strategy to increase production, enhance flexibility in the manufacturing of both existing and future pharmaceutical products, and enable potential contract manufacturing opportunities. German CDMO Axplora has announced a €6.5 million (approximately US$ 7.5 million) investment to expand its API manufacturing capacity at its Vizag site in India. This expansion aims to strengthen both production capabilities and supply chain resilience. India-based Aarti Pharmalabs has inaugurated the first phase of its greenfield manufacturing facility in Gujarat (India). This expansion aims to bolster Aarti's CDMO and contract manufacturing organization (CMO) services, targeting a revenue goal of INR 10 billion (approximately US$ 112 million). Snapdragon Chemistry, which was acquired by Cambrex in 2023, has expanded its Massachusetts facility to better support peptide drug development and manufacturing. With this upgrade, the company can now handle peptide projects from early development through full-scale manufacturing. Italy-headquartered ICE Pharma has expanded its Raichem facility in India. The new facility will enhance the production of ursodeoxycholic acid (UDCA), an API it derives from chicken bile. This expansion increases the site’s raw UDCA output by 120 metric tons annually. Spain-headquartered AGC Pharma Chemicals inaugurated a new advanced manufacturing plant in Barcelona, with an investment of €110 million (approximately US$ 128.3 million). The plant spans 7,500 square meters and integrates cutting-edge technologies to support the entire drug development lifecycle — from R&D to commercial manufacturing. This represents a 30 percent increase in the company’s production capacity and introduces a segment dedicated to HPAPIs. Germany-headquartered Aenova has launched a new hot melt extrusion platform at its Regensburg (Germany) site. This new equipment enables the production of advanced drug formulations, while handling all testing and quality checks in-house. The move strengthens Aenova’s capabilities in developing and manufacturing complex medications. US-based Cytovance Biologics has introduced in-house formulation development services, enhancing its role as a comprehensive partner for biologic drug developers. These services utilize quality-by-design principles to ensure speed, safety, and precision in current and future client programs. View CDMO Activity Tracker for Q3 2025 (Free Excel Available) Ofichem acquires Avivia BV; Evonik, Samsung Biologics form strategic collaborations Europe-based CDMO Ofichem Group announced the acquisition of Avivia BV, a formulation development company in the Netherlands. This acquisition is part of Ofichem’s strategy to become a fully integrated provider of development solutions across both drug substance and drug product, with a focus on complex formulations. Ofichem has also acquired Meribel Pharma Solutions’ site in Uppsala (Sweden) to strengthen its support for biotech innovators and expand its presence in the Nordic region. Simtra BioPharma Solutions has acquired a 65-acre property near its Bloomington, Indiana (US) facility, adding over 300,000 square feet of potential expansion space. With this site, Simtra now has the flexibility to rapidly expand in the US. German specialty chemicals company Evonik is partnering with German biotech Ethris to develop and commercialize a next-generation lipid nanoparticle (LNP) platform for delivering nucleic acid therapies. Evonik will assist in formulation using Ethris’ SNaP LNP technology. The LNP market alone is projected to grow to US$2.3 billion by 2032. Luxembourg-headquartered Fareva has partnered with Zhaoke Ophthalmology to expand its footprint in China’s pharma market. Zhaoke will act as Fareva’s go-to partner for customers seeking pharmaceutical manufacturing in China. Samsung Biologics has signed a 1.8 trillion won (US$ 1.3 billion) manufacturing agreement with an undisclosed US-based drugmaker. And UK-based eXmoor Pharma has partnered with Anthony Nolan to provide end-to-end services for cell therapy developers. View CDMO Activity Tracker for Q3 2025 (Free Excel Available) Our view The global CDMO market, valued at around US$ 255 billion in 2025, is projected to grow to over US$ 465 billion by 2032. Significantly, about 60 percent of new drug approvals in the US and over 65 percent in Europe now involve CDMO support. The developments outlined above underscore the increasing role CDMOs are playing today in bringing about growth and innovation in the pharmaceutical industry.